SPRO:NASDAQSpero Therapeutics, Inc. Analysis

Spero Therapeutics is trading at $2.85, comfortably above its $2.48 support but well below the $3.08 resistance, with a 20‑day SMA of $2.76 sitting above the 50‑day SMA of $2.69, indicating a bullish price trend. The RSI of 55.7 suggests modest momentum, while the MACD histogram is slightly negative, hinting at short‑term bearish pressure. Volatility is high at 65% over the past 30 days and beta exceeds 1.2, underscoring heightened market risk. Fundamentally, the company’s DCF fair value of $3.96 implies roughly 40% upside, yet revenue has collapsed by 95% YoY and operating margins are deeply negative at -29%. Cash on hand ($56.1M) dwarfs debt ($2.5M), providing a solid liquidity cushion despite the weak earnings outlook. The recent Q1 2026 operating results update, while not detailed here, signals ongoing clinical progress that could catalyze a turnaround. Overall, the stock presents a compelling undervaluation relative to its peers (PE 10.6 vs industry 24.8) but carries substantial execution and regulatory risk.